x

Posted 29 June, 2023

THERALINK TECHNOLOGIES, INC. appointed new CEO

CEO Change detected for ticker OTC:THER in a 8-K filed on 29 June, 2023.


  Theralink Technologies, Inc. (the "Company") announces that Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of THERALINK TECHNOLOGIES, INC.
Health Care/Life Sciences • Pharmaceuticals
Theralink Technologies, Inc. is a precision medicine company, which engages in the development of novel cancer immunotherapy products. It offers the reverse phase protein array technology platform that can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. The company was founded on March 18, 2005 and is headquartered in Golden, CO.
Market Cap
$6.15M
View Company Details
THERALINK TECHNOLOGIES, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Theralink Technologies, Inc. (the "Company") announces that Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023. Ms. Zaslavsky has served as the Company's President and Chief Operating Officer since December 2022.


Ms. Zaslavsky has over 23 years of experience in the field of genomics and multiple commercialization successes to her credit. She has made significant contributions to the development of new genomic offerings and the application of genomics to clinical practice, ultimately making genomics more accessible to patients and healthcare providers while building corporate value. Amongst other successes, Ms. Zaslavsky has been instrumental in the commercialization of tests that detect mutations in BRCA1 and BRCA2 genes associated with increased risk of breast and ovarian cancer; provided oversight for tests used to detect mutations in genes associated with Lynch syndrome, a hereditary cancer syndrome; and launched an oncology suite of solutions providing guidance in therapeutic decision making. Cumulatively, these tests inform thousands of physicians, and help treat or prevent countless cases of cancer. Ms. Zaslavsky received a bachelor's degree in Business Administration from Washington State University in 1997.


Ms. Zaslavsky entered into an Offer Letter with the Company on December 5, 2022, which remains in place following her new appointment.


The Company's former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company's Chief Medical Officer.